Insulinoma laboratory tests: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Insulinoma}} | {{Insulinoma}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{ADS}} | ||
==Overview== | ==Overview== | ||
Revision as of 15:02, 2 October 2017
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Insulinoma laboratory tests |
|
Risk calculators and risk factors for Insulinoma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Laboratory findings consistent with the diagnosis of insulinoma include serum glucose < 55 mg/dL[1]; serum Insulin > 5-10 μU/mL; serum C-Peptide > 200 pmol/L and serum proinsulin ≥ 22 pmol/L. Patients with insulinoma may have elevated insulin to glucose ratio > 0.4, which is usually suggestive of insulinoma after a 72-hour fast test as a gold standard test. [2] 1/3 rd or 33% patients have clinical symptoms with in 12 hours of the fasting; 80% develop within 24 hours; 90% develop within 48 hours and 100% develop within 72 hours.
Laboratory Findings
- Laboratory findings consistent with the diagnosis of insulinoma include:
- Serum glucose < 55 mg/dL [1]
- Serum Insulin > 5-10 μU/mL
- Serum C-Peptide > 200 pmol/L
- Serum proinsulin ≥ 22 pmol/L
- Patients with insulinoma may have elevated insulin to glucose ratio > 0.4, which is usually suggestive of insulinoma after a 72-hour fast test. It is a gold standard test. [2]
- 1/3 rd or 33% patients have clinical symptoms with in 12 hours of the fasting
- 80% develop within 24 hours
- 90% develop within 48 hours
- 100% develop within 72 hours
References
- ↑ 1.0 1.1 Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER; et al. (2009). "Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 94 (3): 709–28. doi:10.1210/jc.2008-1410. PMID 19088155.
- ↑ 2.0 2.1 Callender GG, Rich TA, Perrier ND (2008). "Multiple endocrine neoplasia syndromes". Surg Clin North Am. 88 (4): 863–95, viii. doi:10.1016/j.suc.2008.05.001. PMID 18672144.